Home›Daclatasvir

Daclatasvir

3 interactions on record

Daclatasvir has 3 known drug interactions based on U.S. FDA drug labeling data. 1 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Rifampin, Itraconazole. Patients taking Daclatasvir should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.

Total: 3
Major: 1
Moderate: 1

Major (1)

Daclatasvir + Rifampin— Antiretrovirals Prevention or Management: Avoid concomitant use Zidovudine Decrease AUC by 47% Indinavir Decrease AUC by…

Moderate (1)

Daclatasvir + Itraconazole— Antivirals Daclatasvir Indinavir a Maraviroc Monitor for adverse reactions.

Daclatasvir + Rifampin⚠️Major

Antiretrovirals Prevention or Management: Avoid concomitant use Zidovudine Decrease AUC by 47% Indinavir Decrease AUC by 92% Efavirenz Decrease AUC by 26% Cortisol Receptor Blocker Mifepristone Prevention or Management: Avoid concomitant use Decrease exposure Hepatitis C Antiviral Prevention or Management: Avoid concomitant use Daclatasvir Decrease AUC by 79% Simeprevir Decrease AUC by 48% Sofosbuvir Decrease AUC by 72% Coadministration of sofosbuvir with rifampin may decrease sofosbuvir plasma concentrations, leading to reduced therapeutic effect of sofosbuvir.

Daclatasvir + Itraconazole🟡Moderate

Antivirals Daclatasvir Indinavir a Maraviroc Monitor for adverse reactions.

Daclatasvir + Etravirineℹ️Unknown

Hepatitis C virus (HCV) direct-acting antivirals : daclatasvir ↓ daclatasvir Co-administration of etravirine tablets with daclatasvir may decrease daclatasvir concentrations. Increase the daclatasvir dose to 90 mg once daily. Hepatitis C virus (HCV) direct-acting antivirals : daclatasvir ↓ daclatasvir Co-administration of etravirine tablets with daclatasvir may decrease daclatasvir concentrations.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.